Skip to main content

ORAL SURVEILLANCE: Was hat sich an der Risikobeurteilung von JAK-Inhibitoren geändert?

ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?

This is a preview of subscription content, access via your institution.

Literatur

  1. Ytterberg SR, Deepak LB, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316–326

    CAS  Article  Google Scholar 

  2. Charles-Schoeman C, Fleischmann R, Mysler E et al (2021) The risk of venous thromboembolic events in patients with RA aged ≥ 50 years with ≥ 1 cardiovascular risk factor: Results from a phase 3b/4 randomised safety study of tofacitinib vs TNF inhibitors. Arthritis Rheumatol 73(suppl 10):abstract 1941

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea Rubbert-Roth.

Ethics declarations

Interessenkonflikt

A. Rubbert-Roth hat Honorare für Beratung und/oder Vorträge von folgenden Firmen erhalten: AbbVie, Lilly, Pfizer, Gilead, BMS, MSD, Roche, Sanofi, UCB.

Additional information

Redaktion

Christoph Fiehn, Baden-Baden

Bernhard Hellmich, Kirchheim-Teck

Ina Kötter, Hamburg

Klaus Krüger, München

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rubbert-Roth, A. ORAL SURVEILLANCE: Was hat sich an der Risikobeurteilung von JAK-Inhibitoren geändert?. Z Rheumatol (2022). https://doi.org/10.1007/s00393-022-01252-y

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00393-022-01252-y